ReviewCurrent rheumatology reports2013
Update on treatment of inclusion body myositis.
Review in Current rheumatology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Increasing daily duration of rehabilitation for inpatients with sporadic inclusion body myositis may contribute to improvement in activities of daily living: A nationwide database cohort study.Journal of rehabilitation medicine · 2023Article
- Review
- Dysphagia in Patients with Sporadic Inclusion Body Myositis: Management Challenges.International journal of general medicine · 2019Review
- Current Classification and Management of Inflammatory Myopathies.Journal of neuromuscular diseases · 2018Review
- Concomitant occurrence of FXTAS and clinically defined sporadic inclusion body myositis: report of two cases.Croatian medical journal · 2017Article
- Inclusion Body Myositis: A Case Presenting with Respiratory Failure and Autopsy Findings Leading to the Hypothesis of a Paraneoplastic Cause.The American journal of case reports · 2017Article
- Immune and myodegenerative pathomechanisms in inclusion body myositis.Annals of clinical and translational neurology · 2017Review
- Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis.Auto- immunity highlights · 2016Article
- Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.Annals of the rheumatic diseases · 2016Article
- Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.Journal of neurology, neurosurgery, and psychiatry · 2016Article
- Targeting protein homeostasis in sporadic inclusion body myositis.Science translational medicine · 2016Article
- Corticosteroids in Myositis and Scleroderma.Rheumatic diseases clinics of North America · 2016Review
- Misdiagnosis of inclusion body myositis: two case reports and a retrospective chart review.Journal of medical case reports · 2015Article
- Treatment for inclusion body myositis.The Cochrane database of systematic reviews · 2015Review
- Ongoing developments in sporadic inclusion body myositis.Current rheumatology reports · 2014Review
- Sporadic inclusion body myositis: new insights and potential therapy.Current opinion in neurology · 2014Article
- Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders.Current opinion in supportive and palliative care · 2013Review
- Update in inclusion body myositis.Current opinion in rheumatology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Degenerative mechanisms such as protein accumulation and vacuolar transformation in the skeletal muscle distinguish inclusion body myositis (IBM) from other inflammatory myopathies. IBM is particularly common in patients over the age of 50 years and inevitably leads to progressive muscle weakness and atrophy. Conventional immunotherapies, albeit effective in other forms of myositis, seem to have only a transient or no beneficial effect on disease progression of IBM. So far, no established evidence-based treatment exists and therapy recommendations are based on expert opinion. Recent clinical trials using monoclonal antibodies such as alemtuzumab or etanercept have failed to demonstrate efficacy. Different treatment studies with drugs that aim at degenerative disease mechanisms are planned or ongoing. This review aims to provide an overview of the current treatment options for IBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.